Hims & Hers Health Cuts Guidance After Double Miss on $2.6B Revenue

NEW YORK, November 10 —

Hims & Hers Health, Inc. (HIMS) missed on both EPS and revenue while cutting forward guidance, leaving its 31.1x fwd P/E with nowhere to hide.

The Eli Lilly Halo Lasted Exactly Three Days

Last week, HIMS surged on a headline partnership with Eli Lilly that Investor's Business Daily called "surprising and inevitable." Markets priced in the upside before seeing the underlying numbers. The underlying numbers were worse than consensus. That sequencing is the worst possible framing for a high-multiple stock. A rally on a partnership headline, followed by a miss and guidance cut on the same call, suggests the deal was announced to manage sentiment heading into a soft quarter rather than to signal operational strength. The gap-down visible in the chart reflects how quickly the Lilly premium exited the stock. Investors who bought the surge three days ago are now absorbing both a thesis reset and a multiple compression in a single session.

Negative EPS Hides a Business With Real Cash Generation

The number the wire story will not surface: HIMS generates $849mn in free cash flow against $2.6bn in TTM revenue, a roughly 33% FCF margin that is genuinely strong for a growth-stage consumer health platform. The -$0.64 trailing EPS reflects non-cash charges, not a cash-burning operation. The genuine bull case was always FCF generation at scale, not GAAP profitability. The bear case, now confirmed, is simpler: at 31.1x fwd P/E, the multiple assumes the 38.2% YoY revenue growth rate holds. The guidance cut says it will not. At a lower multiple, this remains a real business. The question is what multiple the market assigns a company that just missed and guided down in the same breath. Track how that re-rating develops on the HIMS stock page.

27.6% Short Float Was Pricing This Risk Before the Print

When more than a quarter of the float is sold short, the market is signaling institutional doubt about the growth narrative. That level of positioning does not appear by accident. HIMS went into this report with 27.6% short float, meaning sophisticated money was sizing execution risk well ahead of Tuesday's numbers. A short squeeze is now off the calendar until the company delivers a clean quarter. The new guidance implies that will not arrive in Q4.

Unapproved Peptides Give the Short Side a Second Thesis

Reuters reported this week that HIMS plans to offer unapproved peptides following an easing of U.S. restrictions. That may pad near-term revenue. It also adds a regulatory risk category absent from the original growth thesis. For a stock managing investor confidence after a double miss, moving into gray-area products gives the already-elevated short interest a second argument to press if regulators revisit those restrictions.

The specific number that proves the bull case wrong next quarter is revenue growth decelerating below 30% YoY, the threshold at which that multiple becomes structurally indefensible. Basis Report's full HIMS analysis with a HOLD rating lays out the valuation floor; stress-test the downside scenarios with the DCF calculator.

Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.